Surface-Engineered Porous Silicon Nanoparticles for Targeted Osteosarcoma Therapy.

Area of Science:

• Biomaterials Science
• Nanotechnology
• Oncology

Background:

• Osteosarcoma is an aggressive bone cancer with limited treatment options.
• Targeted nanocarriers offer a promising approach for delivering chemotherapy to bone.
• Developing effective drug delivery systems is crucial for improving osteosarcoma treatment outcomes.

Purpose of the Study:

• To develop and evaluate a bone-targeted nanocarrier system for doxorubicin delivery in osteosarcoma.
• To functionalize porous silicon nanoparticles with alendronate for enhanced bone targeting.
• To assess the drug loading, release kinetics, and in vitro efficacy of the targeted nanocarriers.

Main Methods:

• Synthesis of alendronate-conjugated poly(N-(2-hydroxypropyl)acrylamide)-functionalized porous silicon nanoparticles (ALN-PolyHPAm@D-pSiNPs).
• Evaluation of doxorubicin loading capacity, pH-responsive release, and antifouling properties.
• Assessment of hydroxyapatite-binding affinity and cellular uptake in Saos-2 osteosarcoma cells.
• In vitro cytotoxicity assays comparing targeted nanoparticles with non-targeted nanoparticles and free doxorubicin.

Main Results:

• The developed nanoparticles exhibited high doxorubicin loading capacity and sustained, pH-responsive drug release.
• ALN-PolyHPAm@D-pSiNPs demonstrated strong hydroxyapatite-binding affinity and selective uptake in osteosarcoma cells.
• Doxorubicin-loaded targeted nanoparticles showed significantly enhanced in vitro cytotoxicity against Saos-2 cells compared to controls.

Conclusions:

• The bone-targeted porous silicon nanoparticle platform effectively delivers doxorubicin for osteosarcoma treatment.
• Alendronate conjugation enhances nanoparticle targeting to bone tissue.
• This nanocarrier system holds significant promise for improving osteosarcoma therapy.